Image Credit: Health and me
There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.
The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.
While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.
Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.
While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.
Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.
Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.
RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.
Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.
The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.
Also Read: Is US Preparing For A Quad- demic 2025?
The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:
While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.
If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.
As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.
CREDITS: CANVA
Malfunctioning glucose sensors made by Abbott Diabetes Care have been tied to more than seven hundred serious medical events and seven possible deaths, according to updates from both Abbott and the Food and Drug Administration (FDA). The company issued a public notice on November 24 and sent letters to those who may be affected, explaining that it had begun a “medical device correction” for select FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors.
On December 2, the FDA released an early safety communication, which is the type of alert shared when a product is corrected or removed because of a significant risk before the agency can determine whether an official recall is necessary.
Some FreeStyle Libre 3 sensors may show falsely low blood sugar levels, which can lead people with diabetes to make treatment choices that are not appropriate for their actual condition. When someone’s glucose appears low, they might delay their insulin dose or skip it altogether, or they may eat more carbohydrates in an effort to raise their levels, as noted by USA Today.
When treatment decisions are based on incorrect readings, blood sugar can quickly become unstable. Poor glucose control can result in dangerous medical complications, including injury or even death. Problems linked to mismanaged diabetes can include diabetic ketoacidosis, heart issues, stroke, kidney damage, nerve and eye problems, and a higher chance of infection.
USA Today reports that the issue affects nearly three million Libre 3 and Libre 3 Plus sensors sold in the United States, and Abbott estimates that roughly half of them have already been used or have expired. Worldwide, the company has received 736 reports of severe adverse events (57 in the U.S.) and seven reports of deaths (none in the U.S.) that may be associated with this problem.
Only specific FreeStyle Libre 3 and FreeStyle Libre 3 Plus Continuous Glucose Monitoring Systems are affected. The FreeStyle Libre 3 handheld reader and mobile app are working normally.
No other Libre devices (FreeStyle Libre 14-day, FreeStyle Libre 2, FreeStyle Libre 2 Plus, or the FreeStyle Libre Pro sensors) or Abbott biowearable products are involved.
FreeStyle Libre 3 Sensor
FreeStyle Libre 3 Plus Sensor
The serial number for a FreeStyle Libre 3 or FreeStyle Libre 3 Plus sensor is available in the app or reader, and it is also printed on the label at the bottom of the sensor applicator or on the carton. Consumers who are wearing a sensor that has been confirmed as part of the affected group should stop using it at once and safely discard it.
Credits: Canva
The Centers for Disease Control and Prevention’s vaccine advisory committee will meet on Thursday and Friday to review the childhood vaccination schedule, look at adjuvants and possible contaminants, and revisit hepatitis B immunisation guidance.
This will be the third gathering this year of the Advisory Committee on Immunization Practices (ACIP) after Health and Human Services Secretary Robert F. Kennedy Jr. dismissed all 17 former members and brought in his own choices, many of whom have openly questioned long-standing vaccine policies.
It is also the first meeting since ACIP chair Martin Kulldorff, a former Harvard Medical School professor, accepted a permanent job at HHS. Pediatric cardiologist and former U.S. Air Force flight surgeon Dr. Kirk Milhoan will lead the committee during this session.
The latest battle in the US’ growing political, cultural, and scientific debate over vaccines will unfold inside a CDC meeting room in Atlanta later this week.
There, a key CDC advisory group — now entirely appointed by Kennedy who will vote on proposals that could significantly change long-accepted guidance meant to shield newborns from hepatitis B, a virus known to cause liver cancer.
The two-day ACIP meeting comes shortly after Kennedy instructed the CDC to alter language on its website, downplaying the agency’s long-standing statement that vaccines do not cause autism, even though extensive research has repeatedly found no connection.
Here is what public health experts say they will be watching during this week’s meeting, which will be livestreamed on Thursday and Friday.
According to the meeting agenda, Thursday’s discussions and votes will centre on major changes to hepatitis B guidance. Overnight, the committee released draft wording for two recommendations.
As per CNN, the first proposal would shift the current universal recommendation for newborn hepatitis B vaccination to an “individual-based decision” made by parents and a healthcare provider for babies born to mothers who test negative for the virus or whose status is unknown.
The language also gives parents and clinicians the freedom to “decide when or if their child will begin the HBV series.”
The second vote concerns draft wording that encourages parents to talk with clinicians about blood tests to check immunity levels before later hepatitis B doses. The draft states that insurance should cover these tests.
Currently, all newborns are advised to receive the vaccine shortly after birth to protect against infection from an undetected maternal case and from close contacts who may unknowingly carry the virus.
Committee members have previously urged better hepatitis B screening during pregnancy, while others have questioned whether only high-risk infants should get the vaccine.
Hepatitis B is highly contagious. It spreads through contact with infected blood and bodily fluids, often from people with no symptoms. While it can be passed during birth, through sex, or shared needles, it can also spread through shared items found in many homes: nail clippers, toothbrushes, and even certain pieces of jewellery.
Childhood And Adolescent Immunisation Schedule
It is not yet clear what parts of the schedule will be reviewed. The early agenda listed this topic for Friday without details. The final agenda shows that attorney Aaron Siri, a close adviser to Kennedy, will speak on this.
Critics, including Kennedy, have raised questions about the number of vaccines children receive and the timing between doses.
According to ABC News, the draft agenda included a Friday session on adjuvants and contaminants. The final programme describes the talk as examining aluminium exposure from vaccines before 24 months and rates of persistent asthma between ages 24 and 59 months.
Aluminum salts are used in several vaccines — including diphtheria, tetanus, acellular pertussis, hepatitis A, and hepatitis B—to strengthen the immune response, according to CNN.
The ACIP meeting also follows last week’s internal FDA memo claiming that Covid-19 vaccines may be connected to the deaths of ten children. Lakshmanan, O’Leary, and others say the committee could raise the issue during the discussions.
Credits: AP
US President Donald Trump was seen struggling to stay alert several times during a three-hour Cabinet meeting on Tuesday. Footage showed the 79-year-old president narrowing his eyes again and again and briefly closing them fully, even as Cabinet officials spoke about their work and praised his leadership.
At one point, he appeared to drift off while Commerce Secretary Howard Lutnick addressed the room before shifting forward to reply. His tired look followed a long night on Truth Social, where he posted more than 160 times between 7 p.m. and midnight on Monday and resumed posting shortly before 6 a.m. on Tuesday, which added to the growing discussion around his health.
President Donald Trump seemed to lose focus multiple times during the Dec. 2 Cabinet meeting. He repeatedly narrowed his eyes and, at one moment, kept them fully closed as his team outlined their achievements and spoke in his praise. While Howard Lutnick shared an update on the Commerce Department, Trump kept his eyes shut for several seconds before leaning in to answer him.
The president’s drained appearance followed a night of heavy activity on Truth Social, where he uploaded more than 160 posts from early evening to midnight on Dec. 1. He returned to the platform by 5:48 a.m. the next morning.
When PEOPLE reached out for comment, the White House shared a statement from press secretary Karoline Leavitt. She said, “President Trump was listening closely and leading the three-hour Cabinet meeting,” before repeating a recent administration claim that Somali immigrants do not belong in Minnesota.
She continued, “Watch his strong closing remarks in the press conference, where he called out America-Last Democrats for allowing radical Somali migrants to take advantage of American taxpayers.” She said that this moment captured the energy of Trump’s ninth Cabinet meeting of his second term, all of which have been fully open to the press.
“In each of these meetings,” she added, “the President and his team lay out the long list of accomplishments they have delivered for the American people to Make America Great Again.” Last year, Trump rejected reports that he had fallen asleep during his criminal trial in New York. Multiple outlets had described him slipping into brief naps, with The New York Times noting, “Mr. Trump appeared to nod off a few times, his mouth going slack and his head drooping onto his chest,” which Trump denied.
Donald Trump is once again facing scrutiny over his health after a new video showed him looking sleepy during a Cabinet meeting. His slow eye movements and long pauses with his eyes shut set off fresh conversations online. A separate photograph from Mar-a-Lago, where he appeared with his eyes closed and mouth open, fuelled more worry.
As per PEOPLE, at the same time, an image of Joe Biden looking lively during a walk in Nantucket led to a wave of side-by-side comparisons on social media. The White House maintains that Trump remains in “excellent health”, pointing to recent tests, though his unclear remarks about undergoing an MRI have added to public questions. With both leaders under a microscope, discussions about presidential fitness have returned with new intensity.
The White House on Monday released details from Donald Trump’s MRI, which he completed last month as concerns about his health continued. In a statement, Navy Captain Sean Barbabella, the physician to the president, outlined the results of Trump’s advanced imaging. He said the scan focused on Trump’s heart and abdominal region, showed no issues, and confirmed that the president is in “excellent health”. This type of preventive testing is common for men in his age group.
Even so, with this being his second MRI this year, speculation has grown about whether Trump is dealing with any health problems, and the recent moment where he seemed to fall asleep has heightened that speculation.
© 2024 Bennett, Coleman & Company Limited